




JoBurmester.com

Clinical Research Knowhow






Revision 3

Timeline so far

JoBurmester.com

Clinical Research Knowhow






Summary - purposes of main changes

- New structure
- Increased clarity on scope
- Facilitation of innovation
- Feasibility and practicality – QbD, CtQF and Risk Proportionality
- Transparency
- Improved informed consent



New Structure





Annex 1

Reworking of Revision 2

Responsibilities
of IRB/IEC;
Investigator;
Sponsor

Data
Governance,
investigator and
sponsor

Appendices:

Glossary

IB

Protocol

Essential
Records




Scope

“This guideline applies to interventional clinical trials of investigational products that are intended to be submitted to regulatory authorities. The Principles of GCP in this guideline may also be applicable to other interventional clinical trials of investigational products that are not intended to support marketing authorisation applications in accordance with local requirements.”



Underlying
Philosophy







Principles - Changes

- 11 principles – much more detail!
- Biggest changes:

Principle 7



Principle 10





Annex 1

Responsibilities

- IRB/IEC
- Sponsor*
- Investigator*

Data Governance*

- New section

Appendices


- IB
- Protocol
- Essential Records*

Glossary*

* Substantial changes in these sections



Sponsor Responsibilities





Agreements

JoBurmester.com

Clinical Research Knowhow

Sites and service providers – before initiating activities

Updated when there are changes


Responsibility of sponsor and investigator

Service provider management





Sponsor Oversight



Committees

- Purpose
- Access to data and blinding issues
- Expertise and processes





Data Governance

JoBurmester.com

Clinical Research Knowhow

Large new section

Responsibilities of sponsor and investigators

- Data integrity and traceability
- Data Security


Emphasis on protection of blinding

Data Lifecycle





Data Lifecycle





Summary of common themes



Flexibility and
proportionality

QbD

CtQ



More reference to local
requirements

Ongoing review

Doc retention

Safety reporting



Control of data and records



Implementation Timelines

Principles and Annex 1

EU – 23 July 2025

UK – Spring 2026 (at the same time as
new UK Legislation)

US – Unknown at this time



Annex 2

Draft now available for consultation via Regulators

Focus on:

- Decentralised elements
- Pragmatic elements
- RWD



Areas covered in Annex 2

IRB/IEC

- Consent and confidentiality

Investigator

- Ethics
- Consent
- IMP management
- PI oversight
- Safety assessment and reporting

Sponsor

- Long List!



EMA Updates

- Clinical Trials Regulation fully applicable from January 2025
- CTIS guidance updated regularly
- Latest Inspection Metrics Report
 - Critical findings – highest number in Data Management and Monitoring.
 - Most common findings overall - Documentation (including Source Documentation), Training and Qualification, Investigational Site Protocol Compliance



FDA Updates

- Many changes at FDA
- Some guidance has been removed
- Some new guidances on DCTs, use of AI, Evaluation of Sex Differences, IRBs